Trial Profile
A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Everolimus (Primary) ; Lapatinib (Primary) ; Nilotinib (Primary) ; Pazopanib (Primary) ; Sorafenib (Primary) ; Tremelimumab (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Acronyms MOST plus
- 09 Feb 2024 Planned number of patients changed from 560 to 900.
- 09 Feb 2024 Planned End Date changed from 1 Oct 2026 to 1 Oct 2027.
- 09 Feb 2024 Planned primary completion date changed from 1 Jan 2025 to 1 Jan 2026.